CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Azithromycin 10 mg +2 moredrug
Likely dose
Azithromycin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02707523
NCT02707523Phase 2Completed
CompareCT.gov

Prospective Pilot Clinical Trial of Azithromycin Treatment In RSV-induced Respiratory Failure In Children

University of Alabama at Birmingham·interventional·Posted Mar 14, 2016·Updated Jul 22, 2020

In Brief

A Phase 2 clinical trial evaluating Azithromycin 10 mg, Azithromycin 20mg, and 1 other intervention for Respiratory Syncytial Virus. Completed, enrolled 48 participants across 1 site.

Detailed Summary

This randomized, double-blind, placebo-controlled phase 2 trial will be conducted at a single tertiary pediatric intensive care unit (PICU). The study will include children with RSV infection who were admitted to the pediatric intensive care unit and require respiratory support via positive pressure ventilation (invasive and noninvasive).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 14, 2016
Enrollment StartJan 1, 2016
Primary CompletionFeb 6, 2019
Study CompletionJun 20, 2020
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.3 years ago

Interventions

Azithromycin 10 mgdrug

Azithromycin 20mgdrug

Placebodrug